You have our trilingual online publication in front of you. We hope you will take your time to read it and recommend us further. We are happy to inform you about new publications with our newsletter.
by Thierry Meyssan*
(15 March 2021) The Biden administration is driven by a fanatical ideology borrowed from small groups of left-wing believers.1 It is supported by two powerful lobbies: the military-industrial complex2 on the one hand, and the transnational corporations producing in China on the other. Thierry Meyssan presents this little-known lobby.
by Manlio Dinucci
(15 March 2021) The United States continues to modernise its nuclear strike force, also in Europe. In violation of the Non-Proliferation Treaty it has signed, Italy is housing more and more of these weapons.
by Manlio Dinucci*
(15 March 2021) The United States has developed a new type of nuclear bomb, much smaller and more manageable. It will mass-produce and store them in the European Union, to "guarantee its security".
by Luca Beti
(15 March 2021) Switzerland has been supporting the «ProJoven» vocational training project in Honduras since 2013 to help integrate underprivileged young people in the workforce. The project continues to forge ahead, Covid-19 notwithstanding, and has proved surprisingly adaptable.
Blackout due to lack of maintenance?
by Jakob Wehrli
(February 2021) Without really being aware of it, we are gradually heading towards a blackout – in other words, a prolonged and large-scale power failure in Europe, with catastrophic con-sequences. In recent weeks, this issue has been in the headlines once again.
Against Corona, the FOPH relies on patent-protected medicines and ignores cheaper and, above all, much more effective alternatives
by Werner Vontobel
The Federal Office of Public Health (FOPH) knows how to avoid infection with Corona. But as far as the treatment of the disease is concerned, it has learned nothing. It continues to maintain that the new virus can only be combated with a completely new – and thus patent-protected – drug. Of the many patent-protected candidates, however, only Remdesivir from the US pharmaceutical company Gilead remains. The nine "other important drugs" listed on the homepage are painkillers and anaesthetics for the late phase of the disease.